BLRX: $12M market cap brain cancer drug, earnings Wednesday, ASCO Friday, 3.62% short float. Quietly loading

I’d imagine most of you have never heard of $BLRX, but this week can put it on a lot of retail’s radar.

First patient just dosed in a first-in-human glioblastoma trial. First-in-class mechanism. Works where nothing else does including TMZ-resistant patients. Two abstracts accepted at ASCO 2026 opening this Friday.

Short float 3.62% so not a traditional squeeze but volume has been running 300-400% of average with no public catalyst.

Turning Point Therapeutics had two ASCO abstracts. Bristol Myers acquired them for $4.1B shortly after.

Earnings call Wednesday 8:30am EDT. ASCO Friday.